Oncology
Precision oncology with genomic analysis
Precision Oncology AI
Transform cancer care with AI-powered genomic analysis, treatment planning, and personalized therapy recommendations backed by the latest oncological research.
Genomic Analysis Engine
- ✓Comprehensive Mutation Profiling: Analysis of somatic mutations, copy number variations, and structural variants across 700+ cancer genes
- ✓Tumor Mutational Burden (TMB): Automated calculation and interpretation for immunotherapy eligibility assessment
- ✓Microsatellite Instability (MSI): High-accuracy MSI status determination from NGS data with clinical-grade reliability
- ✓Pharmacogenomics Integration: Germline variant analysis for drug metabolism and toxicity prediction
Treatment Decision Support
- ✓Personalized Therapy Matching: AI-driven selection of targeted therapies, immunotherapies, and clinical trials based on molecular profile
- ✓NCCN Guidelines Integration: Real-time access to latest treatment guidelines with patient-specific recommendations
- ✓Drug Interaction Analysis: Comprehensive screening for chemotherapy interactions and contraindications
- ✓Prognosis Modeling: Survival analysis and outcome prediction using machine learning on clinical and genomic data
Supported Cancer Types
Oncology Workflow Integration
Diagnosis & Staging
AI-powered pathology review, TNM staging automation, and imaging analysis for accurate cancer characterization and staging
Molecular Profiling
Comprehensive genomic sequencing analysis, biomarker identification, and actionable mutation reporting for precision therapy selection
Treatment Planning
Personalized treatment recommendations, clinical trial matching, and multidisciplinary team coordination with evidence-based protocols
Clinical Case Study
Patient Presentation
Case: 62-year-old female with stage IIIA lung adenocarcinoma
Genomics: EGFR L858R mutation, TP53 R273H, high TMB (18 mut/Mb)
Challenge: Multiple treatment options, uncertain immunotherapy benefit
SynThera AI Analysis
Recommendation: Sequential EGFR TKI followed by immunotherapy
Rationale: High TMB suggests immunotherapy benefit post-TKI resistance
Outcome: 34-month progression-free survival (vs. 12-month median)
Result: SynThera's AI analysis identified optimal treatment sequencing, leading to significantly extended progression-free survival compared to standard protocols.
Research Collaborations
Cancer Genomics Research
- • MIT - Computational Cancer Biology
- • Dana-Farber Cancer Institute
- • Memorial Sloan Kettering
- • MD Anderson Cancer Center
Pharmaceutical Partnerships
- • Bristol Myers Squibb - Immuno-oncology
- • Pfizer - Targeted Therapy Development
- • Roche/Genentech - Biomarker Discovery
- • Merck - Clinical Trial Optimization
Transform Your Oncology Practice
Join leading cancer centers using SynThera's AI to deliver precision oncology care. Improve patient outcomes with genomics-driven treatment decisions.